Annual CFF
-$16.04 M
-$3.72 M-30.19%
31 December 2023
Summary:
Trinity Biotech annual cash flow from financing activities is currently -$16.04 million, with the most recent change of -$3.72 million (-30.19%) on 31 December 2023. During the last 3 years, it has fallen by -$13.33 million (-490.65%). TRIB annual CFF is now -114.92% below its all-time high of $107.52 million, reached on 31 December 2015.TRIB Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$4.24 M
+$326.00 K+8.32%
30 September 2024
Summary:
Trinity Biotech quarterly cash flow from financing activities is currently $4.24 million, with the most recent change of +$326.00 thousand (+8.32%) on 30 September 2024. Over the past year, it has increased by +$6.67 million (+274.50%). TRIB quarterly CFF is now -96.17% below its all-time high of $110.73 million, reached on 30 June 2015.TRIB Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$25.24 M
+$6.67 M+35.94%
30 September 2024
Summary:
Trinity Biotech TTM cash flow from financing activities is currently $25.24 million, with the most recent change of +$6.67 million (+35.94%) on 30 September 2024. Over the past year, it has increased by +$40.92 million (+260.96%). TRIB TTM CFF is now -76.91% below its all-time high of $109.30 million, reached on 30 June 2015.TRIB TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TRIB Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -30.2% | +274.5% | +261.0% |
| 3 y3 years | -490.6% | +684.3% | +429.1% |
| 5 y5 years | +4.9% | +180.0% | +494.8% |
TRIB Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -490.6% | at low | -77.5% | +131.5% | at high | +222.2% |
| 5 y | 5 years | -490.6% | +4.9% | -77.5% | +131.5% | at high | +222.2% |
| alltime | all time | -114.9% | +42.7% | -96.2% | +115.6% | -76.9% | +181.6% |
Trinity Biotech Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $4.24 M(+8.3%) | $25.24 M(+35.9%) |
| June 2024 | - | $3.92 M(-79.2%) | $18.57 M(+1452.5%) |
| Mar 2024 | - | $18.85 M(-1169.0%) | $1.20 M(-107.5%) |
| Dec 2023 | -$16.04 M(+30.2%) | -$1.76 M(-27.5%) | -$16.04 M(+2.3%) |
| Sept 2023 | - | -$2.43 M(-81.9%) | -$15.68 M(+0.4%) |
| June 2023 | - | -$13.46 M(-936.8%) | -$15.62 M(-824.0%) |
| Mar 2023 | - | $1.61 M(-214.6%) | $2.16 M(-117.5%) |
| Dec 2022 | -$12.32 M(+104.7%) | -$1.40 M(-40.9%) | -$12.32 M(-15.1%) |
| Sept 2022 | - | -$2.37 M(-154.8%) | -$14.51 M(+12.8%) |
| June 2022 | - | $4.33 M(-133.6%) | -$12.86 M(-37.7%) |
| Mar 2022 | - | -$12.87 M(+258.9%) | -$20.66 M(+243.2%) |
| Dec 2021 | -$6.02 M(+121.6%) | -$3.59 M(+394.1%) | -$6.02 M(-21.5%) |
| Sept 2021 | - | -$726.00 K(-79.1%) | -$7.67 M(+10.5%) |
| June 2021 | - | -$3.47 M(-296.7%) | -$6.94 M(+4186.4%) |
| Mar 2021 | - | $1.76 M(-133.7%) | -$162.00 K(-94.0%) |
| Dec 2020 | -$2.72 M(-63.9%) | -$5.24 M(<-9900.0%) | -$2.72 M(-9.7%) |
| Sept 2020 | - | $0.00(-100.0%) | -$3.01 M(+101.4%) |
| June 2020 | - | $3.31 M(-519.2%) | -$1.49 M(-80.2%) |
| Mar 2020 | - | -$790.00 K(-85.7%) | -$7.56 M(+0.4%) |
| Dec 2019 | -$7.53 M(-55.4%) | -$5.53 M(-465.1%) | -$7.53 M(+17.8%) |
| Sept 2019 | - | $1.51 M(-155.0%) | -$6.39 M(-68.0%) |
| June 2019 | - | -$2.75 M(+263.5%) | -$19.95 M(+16.0%) |
| Mar 2019 | - | -$758.00 K(-82.8%) | -$17.20 M(+1.9%) |
| Dec 2018 | -$16.87 M(+33.4%) | -$4.40 M(-63.5%) | -$16.87 M(+16.6%) |
| Sept 2018 | - | -$12.04 M(<-9900.0%) | -$14.47 M(+242.9%) |
| June 2018 | - | $0.00(-100.0%) | -$4.22 M(-59.2%) |
| Mar 2018 | - | -$434.00 K(-78.2%) | -$10.34 M(-18.2%) |
| Dec 2017 | -$12.64 M(-5.3%) | -$1.99 M(+11.2%) | -$12.64 M(-19.4%) |
| Sept 2017 | - | -$1.79 M(-70.7%) | -$15.68 M(+12.9%) |
| June 2017 | - | -$6.12 M(+123.8%) | -$13.89 M(-5.9%) |
| Mar 2017 | - | -$2.73 M(-45.6%) | -$14.76 M(+10.5%) |
| Dec 2016 | -$13.36 M(-112.4%) | -$5.03 M(<-9900.0%) | -$13.36 M(+112.6%) |
| Sept 2016 | - | $0.00(-100.0%) | -$6.28 M(-45.6%) |
| June 2016 | - | -$7.00 M(+427.4%) | -$11.54 M(-110.9%) |
| Mar 2016 | - | -$1.33 M(-164.9%) | $106.19 M(-1.2%) |
| Dec 2015 | $107.52 M(-7634.7%) | $2.04 M(-138.9%) | $107.52 M(-1.4%) |
| Sept 2015 | - | -$5.25 M(-104.7%) | $109.08 M(-0.2%) |
| June 2015 | - | $110.73 M(>+9900.0%) | $109.30 M(<-9900.0%) |
| Mar 2015 | - | $0.00(-100.0%) | -$377.00 K(-73.6%) |
| Dec 2014 | -$1.43 M | $3.60 M(-171.6%) | -$1.43 M(-1.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2014 | - | -$5.03 M(-579.0%) | -$1.46 M(-140.7%) |
| June 2014 | - | $1.05 M(-200.0%) | $3.58 M(-293.5%) |
| Mar 2014 | - | -$1.05 M(-129.4%) | -$1.85 M(+131.6%) |
| Dec 2013 | -$798.00 K(-87.1%) | $3.58 M(>+9900.0%) | -$798.00 K(-75.4%) |
| Sept 2013 | - | $0.00(-100.0%) | -$3.25 M(-24.8%) |
| June 2013 | - | -$4.37 M(<-9900.0%) | -$4.32 M(-16.7%) |
| Mar 2013 | - | $0.00(-100.0%) | -$5.18 M(-16.3%) |
| Dec 2012 | -$6.19 M(-14.5%) | $1.13 M(-205.4%) | -$6.19 M(-25.8%) |
| Sept 2012 | - | -$1.07 M(-79.6%) | -$8.35 M(-18.8%) |
| June 2012 | - | -$5.24 M(+418.3%) | -$10.28 M(+43.0%) |
| Mar 2012 | - | -$1.01 M(-1.4%) | -$7.19 M(-0.8%) |
| Dec 2011 | -$7.25 M(-74.1%) | -$1.02 M(-65.9%) | -$7.25 M(+55.8%) |
| Sept 2011 | - | -$3.00 M(+39.7%) | -$4.65 M(+182.3%) |
| June 2011 | - | -$2.15 M(+100.8%) | -$1.65 M(-93.8%) |
| Mar 2011 | - | -$1.07 M(-168.1%) | -$26.61 M(-4.9%) |
| Dec 2010 | -$27.98 M(+696.8%) | $1.57 M(>+9900.0%) | -$27.98 M(+1.0%) |
| Sept 2010 | - | $0.00(-100.0%) | -$27.71 M(-10.4%) |
| June 2010 | - | -$27.12 M(+1011.8%) | -$30.92 M(+712.7%) |
| Mar 2010 | - | -$2.44 M(-231.9%) | -$3.81 M(+8.3%) |
| Dec 2009 | -$3.51 M(-830.1%) | $1.85 M(-157.5%) | -$3.51 M(-34.5%) |
| Sept 2009 | - | -$3.21 M(<-9900.0%) | -$5.36 M(+149.8%) |
| June 2009 | - | $0.00(-100.0%) | -$2.15 M(-148.0%) |
| Mar 2009 | - | -$2.15 M(-132.4%) | $4.47 M(+83.6%) |
| Dec 2008 | $481.00 K(-143.4%) | - | - |
| June 2008 | - | $6.62 M(-258.3%) | $2.44 M(-158.3%) |
| Mar 2008 | - | -$4.18 M | -$4.18 M |
| Dec 2007 | -$1.11 M(-102.3%) | - | - |
| Dec 2006 | $48.62 M(+402.3%) | - | - |
| Dec 2005 | $9.68 M(-64.8%) | - | - |
| Dec 2004 | $27.49 M(+310.8%) | - | - |
| Dec 2003 | $6.69 M(+16.3%) | - | - |
| Dec 2002 | $5.76 M(+482.2%) | - | - |
| Dec 2001 | $988.90 K(-92.9%) | - | - |
| Dec 2000 | $13.90 M(+262.1%) | - | - |
| Dec 1999 | $3.84 M(-56.9%) | - | - |
| Dec 1998 | $8.90 M(0.0%) | - | - |
| Dec 1997 | $8.90 M(+122.5%) | - | - |
| Dec 1996 | $4.00 M(-41.2%) | - | - |
| Dec 1995 | $6.80 M(+183.3%) | - | - |
| Dec 1994 | $2.40 M(+380.0%) | - | - |
| Feb 1994 | $500.00 K | - | - |
FAQ
- What is Trinity Biotech annual cash flow from financing activities?
- What is the all time high annual CFF for Trinity Biotech?
- What is Trinity Biotech annual CFF year-on-year change?
- What is Trinity Biotech quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Trinity Biotech?
- What is Trinity Biotech quarterly CFF year-on-year change?
- What is Trinity Biotech TTM cash flow from financing activities?
- What is the all time high TTM CFF for Trinity Biotech?
- What is Trinity Biotech TTM CFF year-on-year change?
What is Trinity Biotech annual cash flow from financing activities?
The current annual CFF of TRIB is -$16.04 M
What is the all time high annual CFF for Trinity Biotech?
Trinity Biotech all-time high annual cash flow from financing activities is $107.52 M
What is Trinity Biotech annual CFF year-on-year change?
Over the past year, TRIB annual cash flow from financing activities has changed by -$3.72 M (-30.19%)
What is Trinity Biotech quarterly cash flow from financing activities?
The current quarterly CFF of TRIB is $4.24 M
What is the all time high quarterly CFF for Trinity Biotech?
Trinity Biotech all-time high quarterly cash flow from financing activities is $110.73 M
What is Trinity Biotech quarterly CFF year-on-year change?
Over the past year, TRIB quarterly cash flow from financing activities has changed by +$6.67 M (+274.50%)
What is Trinity Biotech TTM cash flow from financing activities?
The current TTM CFF of TRIB is $25.24 M
What is the all time high TTM CFF for Trinity Biotech?
Trinity Biotech all-time high TTM cash flow from financing activities is $109.30 M
What is Trinity Biotech TTM CFF year-on-year change?
Over the past year, TRIB TTM cash flow from financing activities has changed by +$40.92 M (+260.96%)